Drug Profile
Aclerastide - Derma Sciences
Alternative Names: [Nle3]-Angiotensin II (1-7); DSC-127; NorLeu3-A(1-7); USB 005Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator University of Southern California
- Developer Derma Sciences; United States Department of Defense; US Biotest Inc
- Class Angiotensins; Hexanoic acids; Peptides; Skin disorder therapies
- Mechanism of Action Angiotensin receptor agonists; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Diabetic foot ulcer
Highest Development Phases
- Suspended Radiation-induced skin damage; Scars
- No development reported Wounds
- Discontinued Diabetic foot ulcer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Wounds(In volunteers) in USA (Ophthalmic, Liquid)
- 25 Jul 2018 Phase-I clinical trials in Wounds (In volunteers) in USA (Ophthalmic) (NCT03615196)
- 12 Nov 2015 Discontinued - Phase-III for Diabetic foot ulcer in Canada (Topical)